Sanofi pays Regeneron $462M to exit I-O R&D pact by Nick Paul Taylor Monday, January 7, 2019 The move gives Sanofi the right to opt-in to two bispecific programs but otherwise leaves each company free to operate independently.
Verily pockets $1B with eyes on partnerships, M&A by Amirah Al Idrus Friday, January 4, 2019 Verily is raising $1 billion that will power new partnerships, “global business development opportunities” and potential acquisitions.
Sanofi invests €80M in BioNTech as cancer mRNA hits clinic by Nick Paul Taylor Friday, January 4, 2019 The agreement comes as BioNTech and Sanofi prepare to start clinical development of the first cancer immunotherapy to emerge from their 2015 pact.
It's a no from Sanofi as it punts MyoKardia drug program deal by Ben Adams Wednesday, January 2, 2019 French Big Pharma Sanofi is walking away from a heart drug disease pact with MyoKardia ahead of data readouts coming later this year.
AbbVie streamlines management team—Chutes & Ladders by Conor Hale Friday, January 4, 2019 AbbVie streamlines management team; FDA taps Flatiron exec for oversight post; and PPD beefs up therapeutics team with new leadership.
Sanofi, Sema4 launch 5-year, real-world digital asthma study by Conor Hale Wednesday, December 5, 2018 Sanofi and Sema4 launched a five-year study of nearly 1,200 asthma patients, incorporating digital tools to better understand the disease.
Genentech’s inhaled JAK1 inhibitor shows promise in asthma by Angus Liu Wednesday, November 21, 2018 Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.
Denali, Sanofi press forward with RIPK1 drug in Alzheimer’s by Arlene Weintraub Tuesday, November 20, 2018 Sanofi laid out $125 million to take a stake in two of Denali's RIPK1 inhibitors, and now one will be tested in three tough-to-treat brain disorders.
Sanofi pays Denali $125M to buy into RIPK1 program by Nick Paul Taylor Thursday, November 1, 2018 The agreement covers small molecules designed to treat multiple neurodegenerative and systemic inflammatory diseases.
